Fibrosis and Angiogenesis after Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy (PDR): Increase or Regress?

Narcisa Ianopol & Bernd Kirchhof
Purpose: To analyze the evolution of fibrosis and angiogenesis after intravitreally injected Bevacizumab in PDR. Methods: Eyes with proliferative diabetic retinopathy were intravitreally injected with 1.25 mg Bevacizumab per injection, 1 month interval between injections. The extension of fibrotic[for full text, please go to the a.m. URL]